High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma

British Journal of Dermatology

Volumn 174, Issue 1, 2016, Pages 146-151

  Zaragoza, J ^a   Caille, A ^a,b   Beneton, N ^c   Bens, G ^d   Christiann, F ^e   Maillard, H ^c   Machet, L ^a,b  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c Centre Hospitalier General   (France)

^d Centre Hospitalier Régional CHR   (France)

^e CH Chateauroux ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IPILIMUMAB; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABSOLUTE LYMPHOCYTE COUNT; ABSOLUTE NEUTROPHIL COUNT; ADULT; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CORTICOSTEROID THERAPY; FEMALE; HUMAN; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PRIORITY JOURNAL; CLINICAL TRIAL; DRUG EFFECTS; KAPLAN MEIER METHOD; LYMPHOCYTE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEUTROPHIL; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHILS; SKIN NEOPLASMS;

EID: 84955607539     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14155     Document Type: Article

References (29)

1. Eggermont AM, Spatz A, Robert C,. Cutaneous melanoma. Lancet 2014; 383: 816-27.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al,. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-403.
3. Garbe C, Eigentler TK, Keilholz U, et al,. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16: 5-24.
4. Ives NJ, Stowe RL, Lorigan P, Wheatley K,. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25: 5426-34.
5. Balch CM, Gershenwald JE, Soong SJ, et al,. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
6. Gaudy-Marqueste C, Archier E, Grob A, et al,. Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma. Eur J Cancer 2014; 50: 1120-4.
7. Robert C, Thomas L, Bondarenko I, et al,. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
8. Wolchok JD, Neyns B, Linette G, et al,. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-64.
9. Hodi FS, O'Day SJ, McDermott DF, et al,. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
10. Lebbé C, Weber JS, Maio M, et al,. Survival follow-up and ipilimumab retreatment for patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 2014; 25: 2277-84.
11. Wilgenhof S, Du Four S, Vandenbroucke F, et al,. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 2013; 36: 215-22.
12. Robert C, Schadendorf D, Messina M, et al,. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013; 19: 2232-9.
13. Weber JS, Kähler KC, Hauschild A,. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-7.
14. Templeton AJ, McNamara MG, Šeruga B, et al,. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106: dju124.
15. Di Giacomo AM, Calabrò L, Danielli R, et al,. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 2013; 62: 1021-8.
16. Simeone E, Gentilcore G, Giannarelli D, et al,. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 2014; 63: 675-83.
17. Ku GY, Yuan J, Page DB, et al,. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116: 1767-75.
18. Delyon J, Mateus C, Lefeuvre D, et al,. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 2013; 24: 1697-703.
19. Di Giacomo AM, Ascierto PA, Queirolo P, et al,. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol 2015; 26: 798-803.
20. Hanaizi Z, van Zwieten-Boot B, Calvo G, et al,. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2012; 48: 237-42.
21. Heagerty PJ, Lumley T, Pepe MS,. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56: 337-44.
22. Barzey V, Atkins MB, Garrison LP, et al,. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. J Med Econ 2013; 16: 202-12.
23. Porrata LF, Ristow K, Habermann T, et al,. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol 2010; 85: 896-9.
24. Troppan K, Deutsch A, Gerger A, et al,. The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Br J Cancer 2014; 110: 369-74.
25. Schmidt S, Suciu S, Cornelis JA,. pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma. J Clin Oncol 2007; 25: 1562-9.
26. Cananzi FC, Dalgleish A, Mudan S,. Surgical management of intraabdominal metastases from melanoma: role of the neutrophil to lymphocyte ratio as a potential prognostic factor. World J Surg 2014; 38: 1542-50.
27. Bambury RM, Teo MY, Power DG, et al,. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol 2013; 114: 149-54.
28. Cedrés S, Torrejon D, Martínez A, et al,. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol 2012; 14: 864-9.
29. Kang MH, Go SI, Song HN, et al,. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer 2014; 111: 452-60.